Amy Galka
Merck & Co.
2 Papers
36 Citations
Amy Galka is an academic researcher from Merck & Co.. The author has contributed to research in topics: Taranabant & 5-Lipoxygenase-Activating Protein Inhibitors. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Evaluation of endo- and exo-aryl-substitutions and central scaffold modifications on diphenyl substituted alkanes as 5-lipoxygenase activating protein inhibitors
Lin Chu,Helen M. Armstrong,Linda L. Chang,Amy F. Cheng,Lawrence F. Colwell,Jisong Cui,Jilly F. Evans,Amy Galka,Mark T. Goulet,Nancy S. Hayes,Jane Lo,John G. Menke,Hyun O. Ok,Debra Ondeyka,Minal Patel,Grace M. Quaker,Heather L. Sings,Stephanie L. Witkin,Annie Zhao,Feroze Ujjainwalla +19 more
TL;DR: A search for a suitable replacement for the central norbornyl scaffold presented in the recently disclosed novel FLAP inhibitors is herein described, as well as the SAR study performed on the endo and exo-aryl groups.
21
Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists.
Helen E. Armstrong,Amy Galka,Linus S. Lin,Thomas J. Lanza,James P. Jewell,Shrenik K. Shah,Guthikonda Ravi N,Quang Truong,Linda L. Chang,Grace M. Quaker,Vincent J. Colandrea,Xinchun Tong,Junying Wang,Sherry Xu,Tung M. Fong,Chun-Pyn Shen,Julie Lao,Jing Chen,Lauren P. Shearman,D. Sloan Stribling,Kimberly Rosko,Alison M. Strack,Sookhee Ha,Lex H.T. Van der Ploeg,Mark T. Goulet,William K. Hagmann +25 more
TL;DR: Sulfonamide analogues of the potent CB1R inverse agonist taranabant were prepared and optimized for potency and selectivity forCB1R, and the most potent representative had good pharmacokinetic and brain levels, but was modestly active in blocking CB1r agonist-mediated hypothermia.
20